NCT05172180View on ClinicalTrials.gov

Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19

CompletedOBSERVATIONAL

Enrollment

105

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

April 1, 2021

Conditions

COVID-19

Interventions

DRUG

Reamberin

the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)

DRUG

Ringer's solution

Ringer's solution at an average daily dose of 8.1 ml/kg/day

Trial Locations (1)

Unknown

Nizhegorodskaya Regional Clinical Hospital named after N.A. Semashko, Nizhny Novgorod

All Listed Sponsors

lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY

NCT05172180 - Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19 | Biotech Hunter | Biotech Hunter